Recent studies have suggested that sodium-glucose cotransporter-2 (SGLT-2) inhibitors, a type of glucose-lowering drug used to treat type 2 diabetes mellitus (T2DM), have demonstrated improved cardiovascular outcomes in patients with HF, including those with HFpEF [5]. This evidence concerns the gene SLC5A2 and hydrops fetalis.